Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and cost-effectiveness analysis: a two-way street.

Drug discovery today - 1 Oct 2011

Chalkidou Kalipso, Rawlins Michael

Abstract excerpt

Genetic and proteomic information can be used to identify those patient groups who are most susceptible to a disease and those who are most likely to respond to particular pharmacological treatments. In this review we discuss the impact of cost-effectiveness analysis (CEA) regarding the way pharmacogenetics are adopted by healthcare systems and also, the potential impact of pharmacogenetics on the way CEA is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug-Related Side Effects and Adverse Reactions
Share to Drug Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Molecular Diagnostic Techniques

Share to Pharmaceutical Preparations

Share to Pharmacogenetics

Share to Proteomics

Source

Identifiers

PMID: 21903176
DOI: 10.1016/j.drudis.2011.08.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and cost-effectiveness analysis: a two-way street.PMID 21903176Read ↗

The Economics of Pharmacogenomics.Semantic proximity Read ↗

Economic evaluation of pharmacogenetic tests.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Semantic proximity Read ↗

Assessing the cost-effectiveness of pharmacogenomics.Semantic proximity Read ↗

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read ↗

Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical PracticeSemantic proximity Read ↗

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.Semantic proximity Read ↗

Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing.Semantic proximity Read ↗

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.Semantic proximity Read ↗

Clinical and moral challenges of pharmacogenomics.Semantic proximity Read ↗

Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy.Semantic proximity Read ↗

Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.